Our Pipeline

Central Nervous System Portfolio

Preclinical

Phase I

Phase II

Phase III

TNX-102 SL   Fibromyalgia (FM)
Mid-Phase III — RESILIENT study enrolling

Mid-Phase III

TNX-102 SL   Posttraumatic Stress Disorder (PTSD)
Phase II start — targeting 3Q 2022

Phase II

TNX-102 SL   Long COVID
Phase II start — targeting 3Q 2022

Phase II

TNX-601 CR   Depression, PTSD, Neurocognitive Dysfunction from Corticosteroids*
Phase II start — targeting 1Q 2023

Phase I

TNX-1300   Cocaine Intoxication / Overdose
Phase II ready

Phase II

TNX-1900   Chronic Migraine
Phase II start — targeting 2H 2022

Phase II

* Pending IND Clearance

Immunology Portfolio

Preclinical

Phase I

Phase II

Phase III

TNX-1500   Organ Transplant Rejection / Autoimmune Disorders
Phase I start — targeting 2H 2022

Preclinical

TNX-1700  Gastric and Colorectal Cancers

Preclinical

Infectious Disease Portfolio

Preclinical

Phase I

Phase II

Phase III

TNX-102 SL   Long COVID
Phase II start — targeting 3Q 2022

Phase II

TNX-1840/TNX-1850   COVID-19 Vaccine

Preclinical

TNX-3500   COVID-19 Small Molecule Antiviral

Preclinical

TNX-801   Smallpox and Monkeypox Preventing Vaccine

Preclinical

Rare Disease Portfolio

Preclinical

Phase I

Phase II

Phase III

TNX-2900   Prader-Willi Syndrome
FDA Orphan Drug Designation

Preclinical